Wilkinson B, Patel KS, Smith K, Walker R, et al. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir Vaccine 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
PMID: 37739888